首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients
【2h】

Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients

机译:热休克蛋白90-β过表达与I期肺腺癌患者生存不良有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Heat shock protein 90-beta (Hsp90-β) is associated with cell proliferation, differentiation and apoptosis and has been investigated as a prognostic factor in many cancers. However, Hsp90-β protein expression in lung adenocarcinoma (ADC) has not been thoroughly elucidated. The aim of this study was to determine the relationship between Hsp90-β expression, clinicopathological parameters and prognosis in lung adenocarcinomas. Seventy-five surgically resected lung adenocarcinomas and matched normal lung tissue samples were obtained to construct a tissue microarray (TMA), including 44 stage IA-IB cases. Then, Hsp90-β protein expression level in lung tissue was evaluated by immunohistochemistry. Kaplan-Meier survival analysis with a Log-rank significance test was used to estimate the survival differences among subgroups according to Hsp90-β expression in lung ADC tissues using SigmaPlot/SigmaStat v10 and 3.5, respectively. Hsp90-β protein expression was significantly upregulated in lung ADC tissues compared to that in the matched normal alveoli (P<0.001) and was associated with tumor differentiation (P<0.001). Furthermore, Hsp90-β over-expression was correlated with poor survival in stage I patients (P=0.026). Increased Hsp90-β expression was associated with reduced overall survival (HR, 2.440; 95% confidence interval, 1.076-5.530; P=0.033). To conclude, our data demonstrated that Hsp90-β protein was over-expressed in lung ADC tumor tissues and was associated with poor outcomes in early stage ADC patients and low pathological grade tumors. These data suggest that Hsp90-β could be a clinically useful biomarker for the prognosis of ADC and an effective anticancer target.
机译:热休克蛋白90-β(Hsp90-β)与细胞增殖,分化和凋亡相关,并且已被研究为许多癌症的预后因素。但是,Hsp90-β蛋白在肺腺癌(ADC)中的表达尚未完全阐明。这项研究的目的是确定肺腺癌中Hsp90-β表达,临床病理参数与预后之间的关系。获得了75例手术切除的肺腺癌和匹配的正常肺组织样本,以构建组织微阵列(TMA),包括44例IA-IB期患者。然后,通过免疫组织化学评估肺组织中Hsp90-β蛋白的表达水平。分别使用SigmaPlot / SigmaStat v10和3.5,采用Log-rank显着性检验的Kaplan-Meier生存分析,根据肺ADC组织中Hsp90-β的表达估计亚组之间的生存差异。与匹配的正常肺泡相比,肺ADC组织中的Hsp90-β蛋白表达显着上调(P <0.001),并且与肿瘤分化有关(P <0.001)。此外,Hsp90-β的过表达与I期患者的不良生存相关(P = 0.026)。 Hsp90-β表达增加与总生存期降低有关(HR,2.440; 95%置信区间,1.076-5.530; P = 0.033)。总而言之,我们的数据表明Hsp90-β蛋白在肺ADC肿瘤组织中过表达,并且与早期ADC患者和低病理等级肿瘤的不良预后相关。这些数据表明,Hsp90-β可能是ADC预后的临床有用生物标志物和有效的抗癌靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号